Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
3.788
-0.012 (-0.31%)
Nov 22, 2024, 4:00 PM EST - Market closed
Nanobiotix Revenue
Nanobiotix had revenue of 9.29M EUR in the half year ending June 30, 2024, with 598.95% growth. This brings the company's revenue in the last twelve months to 42.20M, up 526.17% year-over-year. In the year 2023, Nanobiotix had annual revenue of 36.21M with 658.12% growth.
Revenue (ttm)
42.20M EUR
Revenue Growth
+526.17%
P/S Ratio
n/a
Revenue / Employee
413,765 EUR
Employees
102
Market Cap
172.47M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accuray | 444.20M |
Heron Therapeutics | 137.74M |
Biodesix | 65.56M |
BrainsWay | 38.63M |
Senseonics Holdings | 22.21M |
MediWound | 20.14M |
Caribou Biosciences | 11.48M |
NBTX News
- 11 days ago - NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms - GlobeNewsWire
- 23 days ago - NANOBIOTIX to Participate in Multiple Investor Conferences in November - GlobeNewsWire
- 2 months ago - NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth - GlobeNewsWire
- 2 months ago - Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 5 months ago - NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024 - GlobeNewsWire
- 6 months ago - Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy - GlobeNewsWire
- 6 months ago - NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call - GlobeNewsWire